Q2 2021 Results - Reimagining Medicine

Financial review Conclusion Appendix Participants Company overview Pharmaceuticals Oncology Financial performance Innovation: Pipeline overview Our pipeline projects at a glance References Innovation: Clinical trials Phase 1/2 Phase 3 Registration Total ONCOLOGY 44 26 3 73 PHARMACEUTICALS Cardiovascular, Renal, Metabolism Immunology, Hepatology, Dermatology Neuroscience 58 23 3 84 6 7 1 14 Ophthalmology 265 27 8 2 2 37 0 8 3 0 8 Respiratory Global Health 7 2 0 9 7 1 0 8 BIOSIMILARS 0 2 0 2 Total 102 51 6 159 47 Investor Relations | Q2 2021 Results 1 NOVARTIS | Reimagining Medicine

View entire presentation